Chemotherapy News and Research

Latest Chemotherapy News and Research

New radiofrequency ablation system for treating spinal tumors

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz (JGU) has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

Patients with high-grade noninvasive bladder cancer do not receive recommended care

A new study has found that almost all patients with high-grade noninvasive bladder cancer do not receive complete care as recommended by current guidelines.

11 Jul 2011

Research targets malignant glioma stem cells

Cleveland Clinic researchers have identified a cellular pathway that cancer stem cells use to promote tumor growth in malignant glioma, an aggressive brain tumor.

11 Jul 2011

Charité-Universitätsmedizin Berlin establishes MagForce NanoTherm therapy center for treatment of tumors

Nanostart subsidiary MagForce Nanotechnologies AG, a leading medical technology company focusing on nanomedicine in oncology, announced that the Charité-Universitätsmedizin Berlin published the establishment of its NanoTherm therapy center for the treatment of recurrent brain tumors.

8 Jul 2011

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

TGen presents two key studies at 14th World Conference on Lung Cancer

The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

7 Jul 2011

Hydrogel capsule could simultaneously deliver different types of drugs

Researchers at the Georgia Institute of Technology have designed a multiple-compartment gel capsule that could be used to simultaneously deliver drugs of different types. The researchers used a simple "one-pot" method to prepare the hydrogel capsules, which measure less than one micron.

7 Jul 2011

Smoking, social class may lead to POF in women

POF is not only associated with infertility but also with significantly increased morbidity and mortality, as well as a decreased quality of life equivalent to that of people with type 2 diabetes or rheumatoid arthritis, said Dr. Rumana Islam, from Imperial College, London, UK.

6 Jul 2011

New CRM simulation model for Canadian Partnership Against Cancer

If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Review of non-smoker patient with lung cancer to be presented at IASLC conference

A first-of-its-kind study of a patient with lung cancer who never smoked will be presented today by TGen and the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

6 Jul 2011

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Erlotinib phase III study results on lung cancer presented at IASLC conference

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

MGH researchers discover new plant compounds that block blood vessel growth

Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs - agents that interfere with the development of blood vessels.

2 Jul 2011

Medicare to cover 2 expensive cancer drugs

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer.

2 Jul 2011

The Max Cure Foundation, SWCRF partner to fund pediatric cancer research

The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta.

1 Jul 2011